You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Highly efficient, compact, picosecond green laser for time resolved fluorescence
SBC: ADVR, INC. Topic: NCRRDESCRIPTION (provided by applicant): The primary goal of the Phase I effort is to establish the feasibility of fabricating waveguides to realize a significant, (10 fold), increase in performance in the output power of a picosecond pulsed green laser without increasing the peak pump power. The ultimate goal is to develop a fiber pigtailed, compact, cost-effective 530 nm picosecond laser producing 1 ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Nucleic acid delivery of growth factors and heparan sulfate proteoglycans for enh
SBC: International Medicine and Biomedical Research Topic: NIAMSDESCRIPTION (provided by applicant): In chronic wounds, numerous factors contribute to the diminished healing. Wound healing constituents, including heparan sulfate proteoglycans and numerous growth factors, are essential to normal skin wound healing. Several key growth factors such as FGF, VEGF, and PDGF require heparan sulfate-like polymers as co- receptors or co-activators for growth factor act ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
A NEW BIOSENSOR BASED ON CATASTROPHIC PROTEIN CHANGES
SBC: ATERIS Technologies Topic: NIEHSDESCRIPTION (provided by applicant): This Phase I project will test the idea that mechanostress-sensitive, fluorescent polymers can detect structural changes induced in proteins following reaction of the protein with small molecule inhibitors. This concept will be tested and proven using recombinant acetylcholinesterase (AChE) an enzyme that is known to undergo catastrophic denaturation when it re ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Development of recombinant rhTL1A protein for cancer treatment
SBC: BIOPOWERTECH Topic: NCIDESCRIPTION (provided by applicant): Breast cancer is the most common cause of cancer in women and the second most common cause of cancer death in women in the United States. In 2009, approximately 40,170 women in the US are estimated to die from breast cancer. In most cases, death results from metastasis of breast cancer cells. Cancer patients with metastasis cannot currently be cured. Therefore, ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
A Nanofluidic Nanoplasmonic Platform for Multiplexing Detection of Cancer Biomark
SBC: CFD RESEARCH CORPORATION Topic: NCIDESCRIPTION (provided by applicant): This project aims to develop a novel nanofluidic-nanoplasmonic platform to realize multiplexed monitoring of biological binding processes, specifically for detection of cancer biomarkers in bio-fluids. In contrast to current large-sized, cumbersome surface plasmon resonance (SPR) sensing technology, the proposed device is comprised of a multilayer nanostructure ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Discovery of Inhibitors of PTH-Wnt Signaling Synergy in Bone Cells
SBC: DISCOVERYBIOMED, INC. Topic: NIAMSDESCRIPTION (provided by applicant): Project Summary Description Title: Discovery of Inhibitors of PTH-Wnt Signaling Synergy in Bone Cells. Osteoporosis is a growing problem in the aged and an unfortunately large disease market and burden to the healthcare industry. This debilitating disease costs 18 billion in healthcare costs annually in the US and affects 10 million people in the US and an est ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
New In Vitro Human Liver Toxicity Bioassay System
SBC: Vivo Biosciences Inc Topic: NIEHSDESCRIPTION (provided by applicant): Abstract: The overall goal of this SBIR proposal is to develop and commercialize a new human liver bioassay system for real time, long-term toxicity analysis of chemical agents or drugs in vitro. At present, liver studies are mostly performed using hepatocytes cultured onto synthetic or animal-derived matrices. Unfortunately these models fail to replicate true ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
TARGETED TWO-PHOTON PHOTODYNAMIC THERAPY TRIADS
SBC: SENSOPATH TECHNOLOGIES, INC. Topic: NCIThe objectives are to further the pre-clinical development of unique two-photon activated Photodynamic Therapy (PTD) triads that incorporate a photosensitizer, a tumor receptor targeting group, and an imaging functionality, providing a noninvasive treatment of recurrent and refractory Head and Neck (HandN) tumors deep below the skin surface, in an outpatient setting.
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF AN HA2 DOMAIN BASED PERIODONTITIS VACCINE
SBC: International Medicine and Biomedical Research Topic: N/ADESCRIPTION: ( Applicant's Abstract) Periodontal disease can be diagnosed in >50 percent of adults and may contribute to poor health through oral and systemic infection. The disease process is induced by bacteria and the severity of the disease seems due in large part to the immune response of the host. Over the past decades certain microorganisms have become highly ...
SBIR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
Molecular Heparan Sulfate Delivery in Wound Regeneration
SBC: International Medicine and Biomedical Research Topic: N/ADESCRIPTION (provided by applicant): Tissue engineering, grafting procedures, regeneration, and tissue remodeling are developing therapies with great potential medical value. None of these therapeutic modalities are yet fully effective or predictable. Glycosaminoglycan-decorated proteoglycans such as perlecan, once thought to primarily serve as structural components of extracellular matrix, are no ...
SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health